Related Experiment Video
Updated: Jun 12, 2026

Microtransplantation of Synaptic Membranes to Reactivate Human Synaptic Receptors for Functional Studies
Published on: July 20, 2022
Targeted neuronal reprogramming rescues memory and neural synchrony in Alzheimer's disease
Marcos Galán-Ganga1,2,3, Irene Rodríguez-Navarro1,2,3, Sofía Zaballa1,2,3
1Departament de Biomedicina, Facultat de Medicina, Institut de Neurociències, Universitat de Barcelona, Barcelona, 08036, Spain.
None:
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder and represents a major societal burden. Aging is the strongest risk factor for AD, and partial cellular reprogramming using Yamanaka factors (YFs) has recently emerged as a strategy to counteract age-associated dysfunction. However, the mechanisms by which partial reprogramming ameliorates AD-related phenotypes remain poorly defined. Here, we investigated whether targeted and intermittent expression of YFs in hippocampal neurons restores cognitive function and neural network integrity in the P301S mouse model of tauopathy. We first show that controlled YFs expression in hippocampal neurons increases excitatory synaptic transmission and enhances neural synchrony in GCaMP6-expressing neuronal networks. We then induced intermittent, neuron-specific YFs expression for six months in adult control and P301S mice. This intervention led to a sex-dependent improvement in cognitive and emotional behaviors in P301S mice, accompanied by a reduction in Tau pathology and partial restoration of epigenetic aging markers. At the molecular level, reprogramming restored the composition and signaling of N-methyl-D-aspartate receptor (NMDAR) macro-complexes, including key subunits and AD-associated risk factors such as proline-rich tyrosine kinase 2 (PYK2/PTK2B). Importantly, impaired hippocampal neural synchrony observed in P301S mice was also rescued. Together, these findings demonstrate that targeted, partial in vivo neuronal reprogramming reverses behavioral and network-level deficits in a mouse model of AD and identify NMDAR-associated signaling as a potential mechanistic mediator of this effect.
More Related Videos
09:44Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
Published on: May 2, 2025
05:40AAV Systems and Mouse Models for Investigating Ectopic Expression of Neurod1 in Transduced Cells at Subacute and Chronic Times Post-Ischemic Stroke
Published on: November 29, 2024
Related Concept Videos
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology
Alzheimer Disease l: Introduction